Detail akcie Nektar Therapeut Rg online

Business Summary: Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Nektar Therapeutics revenues decreased 44% to $55.2M. Net loss increased 38% to $164.1M. Revenues reflect United States segment decrease from $1.4M to $0K. Higher net loss reflects Interest income decrease of 28% to $10.4M (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$8.68 to -$9.73.